It demonstrated that atezolizumab significantly improved DFS in patients with stage II-IIIa NSCLC with Programmed death-ligand 1 (PDL1) expression greater than or equal to 1%, when compared to patients who did not receive anti-PDL1 treatment. Here, CD274 is linked to non-small cell lung carcinoma.